Health economic evaluation of the use of drug-eluting stents First results from the Drug-Eluting Stent Registry (DES.de)

The purpose of the economic evaluation of the German Drug-Eluting Stent (DES) registry includes the investigation of the economic impact and cost-effectiveness of DES compared to bare-metal stents (BMS) and between paclitaxel-eluting (PES) and sirolimus-eluting stents (SES). Here, methodology and initial results are presented. Patients were recruited in 2005 and 2006 in 87 centres across Germany. Selection of PES, SES, or BMS was made at the discretion of the cardiologists in charge. Clinical, economic, and quality of life (QoL) data were collected at baseline and up to 12 months. Group comparisons were conducted using Fisher's exact and t test. Overall, 3,930 patients were enrolled: 3,471 (75% male, 65 +/- 11 years) received DES and 458 (74% male, 67 +/- 11 years) BMS. Among the DES patients, 1,821 received PES (75% male, 65 +/- 10 years) and 1,600 SES (76% male, 65 +/- 11 years). There were baseline differences in clinical and procedural characteristics but not in QoL. During the hospital stay, major adverse cardiac and cerebrovascular events occurred in 1.6% of DES (PES 1.9%, SES 1.1%) and 2.2% of BMS patients (BMS vs. DES, PES, and SES p = 0.327, 0.706, and 0.098, respectively). Hospital treatment costs were 4,989 +/- 1,284 a,not sign and 3,609 +/- 924 a,not sign, respectively, in DES and BMS patients (p < 0.001) with no significant difference between PES and SES. The economic evaluation of the large DES registry demonstrates increased initial hospitalisation costs associated with DES compared to BMS. Further analysis of the economic impact and cost-effectiveness of DES will provide estimates on large "real world" patient populations for decision makers and aid in reimbursement decisions of DES within the German and other health care systems.